YOLFTbeta
Unicycive Therapeutics Inc

Unicycive Therapeutics Inc

UNCY · NASDAQ · Healthcare / Biotechnology

3.55USD-0.09 (-2.47%)

Price History

Full chart

Market Stats

Previous Close3.64
Open3.63
Day Range3.52 – 3.69
52-Week Range3.93 – 8.74
Volume679.93K
Market Cap128.61M
P/E (TTM)0.00
Forward P/E1.51
EPS-1.75
Dividend Yield0.00%
Beta1.78
50-Day Avg5.20
200-Day Avg6.36

About

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Shalabh K. Gupta M.D., MPA
  • Employees21
  • Headquarters1975 West El Camino Real, Mountain View, CA, United States, 94040, USA
  • Websitehttps://unicycive.com

Leadership

  • Dr. Shalabh K. Gupta M.D., MPAFounder, Chairman, CEO & President · b. 1973
  • Dr. Pramod Gupta Ph.D.Executive Vice President of Pharmaceutical and Business Operations · b. 1960
  • Mr. Douglas Jermasek M.B.A.Executive Vice President of Corporate Strategy · b. 1961
  • Mr. John W. Townsend CPAChief Financial Officer · b. 1962

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-000951.00K675.00K00
Growth (%)------29.02%-100.00%-
Cost of Revenue---1.00K7.00K284.00K428.00K572.00K
Gross Profit----1.00K951.00K675.00K-428.00K-572.00K
Gross Margin----100.00%100.00%--
Operating Expense---8.98M19.00M21.45M31.69M28.95M
Operating Income-952.00K-1.96M-2.02M-8.98M-18.05M-20.77M-32.12M-29.52M
Operating Margin-----1898.21%-3077.63%--
EBITDA--2.03M-2.02M-8.96M-17.89M-30.18M-36.23M-25.91M
EBITDA Margin-----1881.28%-4470.81%--
Net Income-1.12M-2.30M-2.51M-10.63M-18.06M-30.54M-36.73M-26.55M
Net Income Margin-----1899.47%-4525.04%--
R&D344.00K795.00K1.01M6.08M12.44M12.90M20.01M9.12M
R&D as % of Total Revenue----1307.68%1911.41%--
Interest Expense0139.00K244.00K628.00K6.00K82.00K71.00K71.00K
Interest Expense % of Total Revenue----0.63%12.15%--

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets29.00K19.00K204.00K18.74M2.82M14.19M31.67M49.13M
Total Liabilities1.24M903.00K2.88M2.26M3.28M18.00M24.24M18.94M
Total Equity-1.21M-884.00K-2.67M16.48M-466.00K-3.81M7.43M30.20M
Cash25.00K15.00K016.58M455.00K9.70M26.14M29.20M
Total Debt1.05M460.00K2.51M335.00K201.00K811.00K773.00K199.00K
Net Debt1.02M445.00K2.51M-16.24M-254.00K-8.89M-25.37M-29.00M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-775.00K-1.18M-1.46M-5.77M-15.65M-18.28M-28.57M-31.32M
Investing Cash Flow-29.00K-29.00K-29.00K-29.00K-2.00K-12.00K-72.00K-12.10M
Financing Cash Flow800.00K1.17M1.44M22.38M-471.00K27.54M45.09M46.47M
Capital Expenditure29.00K29.00K29.00K29.00K2.00K12.00K72.00K24.00K
Free Cash Flow-775.00K-1.18M-1.46M-5.80M-15.65M-18.30M-28.65M-31.34M
Dividends Paid-----867.00K1.09M0
FCF to OCF100.00%100.00%100.00%100.50%100.01%100.07%100.25%100.08%
Dividend Paid to FCF------4.74%-3.82%0.00%

Earnings

Report DateSep 15, 2020Nov 2, 2020May 21, 2021Aug 16, 2021Nov 12, 2021Mar 31, 2022May 12, 2022Aug 15, 2022Nov 14, 2022Mar 31, 2023May 16, 2023Aug 14, 2023Nov 14, 2023Mar 28, 2024May 13, 2024Aug 14, 2024Nov 13, 2024Mar 31, 2025May 14, 2025Aug 14, 2025Nov 12, 2025Mar 30, 2026May 12, 2026Aug 12, 2026Nov 11, 2026
EPS Estimate0.000.000.00-1.10-1.00-0.13-1.90-2.27-2.80-0.24-3.72-3.20-1.30-0.17-1.55-1.92-1.52-0.09-0.62-0.70-0.53-0.46-0.48-0.34-0.32
EPS Actual-0.03-0.06-0.07-1.30-3.70-0.24-2.40-2.40-3.70-0.35-9.70-2.90-1.30-0.22-6.101.50-0.500.25-0.50-0.52-0.33-0.82-0.54-0.06-
Surprise----18.18%-270.00%-84.62%-26.32%-5.73%-32.14%-45.83%-160.75%9.38%0.00%-29.41%-293.55%178.13%67.11%373.52%19.35%25.71%37.74%-78.26%-11.47%82.35%-
Timing---Pre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-market-Pre-marketPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap128.61M
Enterprise Value73.58M
Trailing P/E0.00
Forward P/E1.51
Price / Sales23.75
Price / Book2.52
EPS-1.75
Book Value1.91
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-33.09M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-101.07%
Return on Assets-40.59%
Shares Outstanding27.39M
Shares Float27.23M
Beta1.78
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 29.60
  • Strong Buy
    4
  • Buy
    3

Ownership Breakdown

Institutions
42.26%
Insiders
2.26%
Retail / Other
55.48%

Top Institutional Holders

  • Octagon Capital Advisors LP
    1.00M3.59%
  • Nantahala Capital Management, LLC
    939.20K3.37%
  • Vanguard Capital Management, LLC
    811.43K2.91%
  • Vivo Capital, LLC
    550.00K1.97%
  • Logos Global Management LP
    473.56K1.70%
  • Diadema Partners LP
    303.68K1.09%
  • Millennium Management LLC
    271.46K0.97%
  • Geode Capital Management, LLC
    203.74K0.73%
  • Susquehanna International Group, LLP
    199.22K0.72%
  • Morgan Stanley - Brokerage Accounts
    188.18K0.68%
  • Marshall Wace Asset Management Ltd
    154.94K0.56%
  • Dauntless Investment Group, LLC
    147.09K0.53%
  • Dimensional Fund Advisors, Inc.
    143.05K0.51%
  • BNP Paribas Arbitrage, SA
    119.53K0.43%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    805.72K2.89%
  • iShares Russell 2000 ETF
    606.92K2.18%
  • Fidelity Small Cap Index
    267.14K0.96%
  • iShares Russell 2000 Growth ETF
    203.29K0.73%
  • PPF Helix Biotechnology I USD
    160.00K0.57%
  • Vanguard Russell 2000 ETF
    140.52K0.50%

Stock Splits

  • Jun 20, 20251:10